Analysts expect argenx SE – (NASDAQ:ARGX) to post earnings of ($0.85) per share for the current quarter, Zacks reports. Three analysts have issued estimates for argenx’s earnings, with the highest EPS estimate coming in at ($0.66) and the lowest estimate coming in at ($1.01). The company is expected to announce its next earnings report on Monday, January 1st.
On average, analysts expect that argenx will report full year earnings of ($3.68) per share for the current fiscal year, with EPS estimates ranging from ($4.45) to ($3.25). For the next year, analysts forecast that the business will post earnings of ($5.02) per share, with EPS estimates ranging from ($6.03) to ($3.85). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for argenx.
Several brokerages have recently weighed in on ARGX. Wedbush upped their target price on shares of argenx from $130.00 to $131.00 and gave the company an “outperform” rating in a research note on Tuesday, December 4th. Zacks Investment Research cut shares of argenx from a “buy” rating to a “hold” rating in a report on Monday, December 24th. Stifel Nicolaus reaffirmed a “buy” rating on shares of argenx in a report on Monday, February 4th. Wolfe Research initiated coverage on shares of argenx in a research report on Friday, December 14th. They issued an “outperform” rating for the company. Finally, ValuEngine upgraded shares of argenx from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. One analyst has rated the stock with a sell rating and thirteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $140.91.
ARGX traded down $1.42 during trading on Friday, hitting $127.49. 3,606 shares of the company’s stock were exchanged, compared to its average volume of 151,156. argenx has a 1 year low of $63.81 and a 1 year high of $135.58. The company has a market cap of $4.09 billion, a P/E ratio of -54.33 and a beta of 1.23.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Story: Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.